It should be noted that CEACAM1 is expressed in 60–80% of metastatic melanoma cases, which suggests that the majority of metastatic melanoma patients would benefit from anti-CEACAM1 antibodies. The gene discussed is CEACAM1; the disease is metastatic melanoma.